Rhythm Biosciences (ASX: RHY) might be returning to some sense of reality here. Or maybe it's just a coming off the top of a significant price rise. For the RHY share price that went up 85% yesterday has come down 14% today. The one doesn't wipe out the other, that's not the way that percentages work. But the fall does bring that price closer at least to what we think is a reasonable valuation. For we believe that there's a misbelief out there, a misunderstanding of what Rhythm has actually gained in this UKCA.
As we said yesterday about Rhythm Biosciences, the supposition seems to be that a UKCA is akin to an FDA approval. FDA approvals are vital to be able to sell in the US market. FDA approvals come at the end of a decade long testing process and the expenditure of at least tens of millions of dollars. The FDA tests for both efficacy and efficiency and so gaining that FDA approval really is a significant valuation point for an entire company. Like, perhaps 85% on the share price levels of re-valuation. So, if the UKCA is similar in either form or effect to the FDA approval then that sort of share price movement is just great, justifiable even.

Rhythm Biosciences share price from ASX
If, however, the UKCA is something different, not akin to FDA approval, the share price reaction to having gained it might, or should, be different. And the UKCA that RHY has received is very different from the FDA approval.
It's entirely true that a UKCA (which is the new update, post-Brexit, to the EU's CE Mark) is a necessary document to have to sell in the UK market. But it's not - not in the least or in any manner - like an FDA approval. To gain a UKCA you fill out the documents properly - remember to spell the company name right, that sort of thing - had over the cheque for £500 and you gain your UKCA. Much of it is in fact self-certification.
There's nothing wrong with any of this, of course there isn't. But it is necessary to know the difference between the two types of document, FDA and UKCAS. Because the share price at Rhythm has reacted as if a UKCA is somehow akin to an FDA approval. And it's nothing like that at all. It's more like deciding upon the packaging. It's just a routine part of the bureaucracy, and it's not something that is denied or approved for any reason other than filling out the form properly - and paying the £500 of course. A UKCA simply isn't worth the $60 million uplift in market capitalisation that this news has caused. Sure, it's a necessary step but the list of companies who have been denied a UKCA is very short indeed. Entirely unlike FDA approval.



